NCT00001136View on ClinicalTrials.gov

A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 2001

Conditions

HIV InfectionsHIV Seronegativity

Interventions

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

Trial Locations (6)

14642

Univ. of Rochester AVEG, Rochester

21205

JHU AVEG, Baltimore

35294

UAB AVEG, Birmingham

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

63110

St. Louis Univ. School of Medicine AVEG, St Louis

98104

UW - Seattle AVEG, Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001136 - A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine | Biotech Hunter | Biotech Hunter